SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Coherus BioSciences: Pure Play In The Emerging Biosimilar In -- Ignore unavailable to you. Want to Upgrade?


To: DewDiligence_on_SI who wrote (7)2/11/2015 9:42:29 PM
From: Arthur Radley  Respond to of 9
 
Was a good presentation! Yesterday and today, I hope is merely a case of profit taking from the near straight up run we've had in the stock over recent weeks. I broke a cardinal rule this week when I had a double, where normally I would take half off the table and get a free ride. I hope I was right!

I own another biotech that also presented today at Leerink's conference. If you don't mind and have the time, listen to their presentation and give me your take on what was said by the CEO. This one is in early stages--Phase 1/2, but IMO is a very exciting area of development, with them have a 'switch' mechanism to help solve the GvHD in mismatched transplants. The company is a local one ---Bellicum (BLCM)
This is a link for today's presentation.
ir.bellicum.com



To: DewDiligence_on_SI who wrote (7)2/17/2015 10:04:49 AM
From: Arthur Radley  Respond to of 9
 
JP Morgan increased target price to $35 with an overweight rating. (Today)